Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment

Abstract Purpose The phosphoinositide 3‐kinase (PI3K)/protein kinase B (AKT) pathway controls insulin sensitivity and glucose metabolism. Hyperglycemia is one of the most common on‐target adverse effects (AEs) of PI3K/AKT inhibitors. As several PI3K and AKT inhibitors are approved by the United Stat...

詳細記述

保存先:
書誌詳細
主要な著者: Dazhi Liu, Michael A. Weintraub, Christine Garcia, Marcus D. Goncalves, Ann Elizabeth Sisk, Alissa Casas, James J. Harding, Stephen Harnicar, Alexander Drilon, Komal Jhaveri, James H. Flory
フォーマット: Artigo
言語:Inglês
出版事項: Wiley 2022-04-01
シリーズ:Cancer Medicine
主題:
hyperglycemia
PI3K/AKT inhibitors
risk factors
SGLT2 inhibitors
toxicity management
オンライン･アクセス:https://doi.org/10.1002/cam4.4579
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料